COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10000 participants.
Also called NCT05633810
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 10,000 participants
- Sponsor
- Registry
-
NCT05633810
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Canada, Denmark, Finland, France, Greece, Italy, Portugal
- Registry status
- Recruiting
Technical summary
Registry record NCT05633810. Randomized; quadruple masking; primary purpose prevention. Start 2022-12-21 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
- Acronym
- COLCOT-T2D
- Condition
- Diabete Type 2
- Condition
- Cardiovascular Diseases
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Aspirin Placebo
- Intervention (Drug)
- Colchicine
- Intervention (Drug)
- Colchicine Placebo
- Lead sponsor
- Montreal Heart Institute
Record details
- Record id
cardio:ct-nct05633810- Content hash
ae0cc9b370544816908de8aae1fa1dfd07cfa4d9656ae79b49b2d464efb647d2